Examining the Target Population of Orphan Drugs: Are Drugs Exceeding the Intended Purposes of the Orphan Drug Act?

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.04.608
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Psy60 - Orphan Versus Ultra-Orphan Drugs Prices in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Are Orphan Drugs Treated the Same Across Europe: An Hta Case Study

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2016English

Mechanism of Coordinated Access to Orphan Drugs

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2012English

Rare Diseases, Drug Development, and AIDS: The Impact of the Orphan Drug Act

Milbank Quarterly
Health PolicyPublic HealthOccupational HealthEnvironmental
1995English

Economic Impact of the End of the Market Exclusivity for Orphan Drugs

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Psy150 - Inequity of Orphan Drugs Prices in Europe

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy135 - Access to Orphan Drugs – Regulation Within the European Law

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Psy147 - Availability and Reimbursement of Orphan Drugs in the Czech Republic

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Reimbursement of Orphan Drugs: The Pompe and Fabry Case in the Netherlands

Orphanet Journal of Rare Diseases
MedicineGeneticsPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy